Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II study
- 1 December 1998
- journal article
- clinical trial
- Published by Elsevier in Lung Cancer
- Vol. 22 (3) , 243-250
- https://doi.org/10.1016/s0169-5002(98)00082-8
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Gemcitabine—a safety reviewAnti-Cancer Drugs, 1998
- PP48. A review of the pharmacoeconomic research on Gemcitabine (GemzarTM) in the treatment of advanced non-small cell lung cancerEuropean Journal Of Cancer, 1997
- Single-agent gemcitabine versus cisplatin-etoposide: Early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancerAnnals of Oncology, 1997
- Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study.Journal of Clinical Oncology, 1997
- Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II studyEuropean Journal Of Cancer, 1996
- Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumour-related symptomsAnti-Cancer Drugs, 1995
- Patterns of cigarette sales and lung cancer mortality in some central and eastern European countries, 1960-1989Cancer, 1995
- Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study.Journal of Clinical Oncology, 1994